Variation of serum PCIII and its clinical significance in patients with essential hypertension before and after treatment with valsartan

Objective To evaluate the impact of valsartan on myocardium fibrosis and left ventricular diastolic function in essential hypertensions(EH).Methods Serum levels of PCⅢ,AngⅡ and left diastolic function parameters in 16hypertension accompanied with left ventricular hypertrophy patients(LVH group) and 18 hypertension without left ventricular hypertrophy patients(NLVH group) were detected by doppler echocardiogram and radioimmunology analyses before and after valsartan treatment,and compared with 15 healthy volunteers(control group). Results Serum levels of PCⅢ and AngⅡ increased in hypertensive patients as compared with normotensive subjects before valsartan treatment(P0.05,P0.01).After treatment,the serum PCⅢ level in patients of 2 groups were decreased(P0.05),and AngⅡ level was increased(P0.05).PCⅢ level positively correlated with the SBP,DBP,LVMI(r=0.587,0.514,0.825,P0.05),and inversely correlates with the ratio of E/A(r=-0.762,P0.05).Conclusions Serum PCⅢ level is an useful marker in reflecting the degree of cardiac muscle collogen synthesis and myocardial fibrosis associated with hypertension.Valsartan may ameliorate the left ventricular diastolic function and prevent myocardium fibrosis.